247 related articles for article (PubMed ID: 31626724)
1. The antiproliferative peptide Ctn[15-34] is active against multidrug-resistant yeasts Candida albicans and Cryptococcus neoformans.
de Aguiar FLL; Cavalcante CSDP; Dos Santos Fontenelle RO; Falcão CB; Andreu D; Rádis-Baptista G
J Appl Microbiol; 2020 Feb; 128(2):414-425. PubMed ID: 31626724
[TBL] [Abstract][Full Text] [Related]
2. Anti-fungal activity of Ctn[15-34], the C-terminal peptide fragment of crotalicidin, a rattlesnake venom gland cathelicidin.
Cavalcante CS; Falcão CB; Fontenelle RO; Andreu D; Rádis-Baptista G
J Antibiot (Tokyo); 2017 Mar; 70(3):231-237. PubMed ID: 27876749
[TBL] [Abstract][Full Text] [Related]
3. Insights into the candidacidal mechanism of Ctn[15-34] - a carboxyl-terminal, crotalicidin-derived peptide related to cathelicidins.
Cavalcante CSP; de Aguiar FLL; Fontenelle ROS; de Menezes RRPPB; Martins AMC; Falcão CB; Andreu D; Rádis-Baptista G
J Med Microbiol; 2018 Jan; 67(1):129-138. PubMed ID: 29214974
[TBL] [Abstract][Full Text] [Related]
4. In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans.
Ghannoum MA; Fu Y; Ibrahim AS; Mortara LA; Shafiq MC; Edwards JE; Criddle RS
Antimicrob Agents Chemother; 1995 Nov; 39(11):2459-65. PubMed ID: 8585726
[TBL] [Abstract][Full Text] [Related]
5. Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study.
Anaissie EJ; Paetznick VL; Ensign LG; Espinel-Ingroff A; Galgiani JN; Hitchcock CA; LaRocco M; Patterson T; Pfaller MA; Rex JH; Rinaldi MG
Antimicrob Agents Chemother; 1996 Oct; 40(10):2387-91. PubMed ID: 8891149
[TBL] [Abstract][Full Text] [Related]
6. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
Franzot SP; Casadevall A
Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188
[TBL] [Abstract][Full Text] [Related]
7. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.
Ernst EJ; Klepser ME; Pfaller MA
Antimicrob Agents Chemother; 2000 Apr; 44(4):1108-11. PubMed ID: 10722525
[TBL] [Abstract][Full Text] [Related]
8. Antibiofilm Activity on
Aguiar FLL; Santos NC; de Paula Cavalcante CS; Andreu D; Baptista GR; Gonçalves S
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33172206
[TBL] [Abstract][Full Text] [Related]
9. In vitro synergic antifungal effect of MUC7 12-mer with histatin-5 12-mer or miconazole.
Wei GX; Bobek LA
J Antimicrob Chemother; 2004 May; 53(5):750-8. PubMed ID: 15073161
[TBL] [Abstract][Full Text] [Related]
10. Enhanced activity of antifungal drugs using natural phenolics against yeast strains of Candida and Cryptococcus.
Faria NC; Kim JH; Gonçalves LA; Martins Mde L; Chan KL; Campbell BC
Lett Appl Microbiol; 2011 May; 52(5):506-13. PubMed ID: 21332761
[TBL] [Abstract][Full Text] [Related]
11. [Susceptibility of yeasts to antifungal agents in Kaunas University of Medicine Hospital].
Skrodeniene E; Dambrauskiene A; Vitkauskiene A
Medicina (Kaunas); 2006; 42(4):294-9. PubMed ID: 16687901
[TBL] [Abstract][Full Text] [Related]
12. Antifungal drug resistance in pathogenic fungi.
Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
[TBL] [Abstract][Full Text] [Related]
13. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.
Klepser ME; Wolfe EJ; Pfaller MA
J Antimicrob Chemother; 1998 Mar; 41(3):397-401. PubMed ID: 9578168
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial Octapeptin C4 Analogues Active against Cryptococcus Species.
Chitty JL; Butler MS; Suboh A; Edwards DJ; Cooper MA; Fraser JA; Robertson AAB
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158283
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans.
De Logu A; Saddi M; Cardia MC; Borgna R; Sanna C; Saddi B; Maccioni E
J Antimicrob Chemother; 2005 May; 55(5):692-8. PubMed ID: 15772140
[TBL] [Abstract][Full Text] [Related]
16. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
Warnock DW; Johnson EM; Rogers TR
J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
[TBL] [Abstract][Full Text] [Related]
17. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
[TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida spp.
Del Poeta M; Bixel AS; Barchiesi F; Tidwell RR; Boykin D; Scalise G; Perfect JR
J Antimicrob Chemother; 1999 Aug; 44(2):223-8. PubMed ID: 10473229
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibitory action of ebselen on fluconazole-resistant Candida albicans: role of the plasma membrane H+-ATPase.
Billack B; Santoro M; Lau-Cam C
Microb Drug Resist; 2009 Jun; 15(2):77-83. PubMed ID: 19432523
[TBL] [Abstract][Full Text] [Related]
20. In vitro antifungal activities of Bay n 7133 and Bay L 9139, two new orally absorbed antifungal imidazole derivatives, against pathogenic yeasts.
Fromtling RA; Yu HP; Shadomy S
Mycopathologia; 1984 Apr; 86(1):45-50. PubMed ID: 6330557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
